Table 1.

EC50 (╬╝mol/L) comparison of prexasertib and SOC in pediatric cancer cell lines

Cell lineCancer typePrexasertibDoxorubicinCisplatinGemcitabine
MOLT-4<0.0010.0261.1210.014
MOLT-3Acute lymphocytic leukemia<0.0010.0060.2270.003
CCRF-CEM<0.0010.0361.4430.017
RD-ESEwing sarcoma0.0030.2672.9440.070
SK-NM-C<0.0010.0740.2140.010
DAOYMedulloblastoma<0.0010.0721.1700.035
D238<0.0010.1382.4070.007
KELLY<0.0010.0301.6600.002
TGWNeuroblastoma0.0010.1903.4990.029
IMR-32<0.0010.0100.0050.004
SH-SY5Y<0.0010.0380.4200.034
SJSA10.001>0.20013.260>0.200
HOSOsteosarcoma<0.0010.0406.774>0.200
SAOS-20.0010.0431.4450.002
Y79Retinoblastoma0.0010.0281.3830.001
A204Rhabdoid<0.0010.0272.4000.003
TE 381.T0.0010.0262.0400.003
SJCRH30Rhabdomyosarcoma<0.0010.0071.3840.001
RD<0.0010.0130.7810.002